Pharmaceutical Technology3 小时
Calquence by AstraZeneca for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.
Pharmaceutical Technology4 小时
Nivolumab by Bristol-Myers Squibb for Neuroendocrine Tumors: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Neuroendocrine Tumors.